BUSINESS
Sun Pharma: Fully valued, though performance impressive
Sales of specialty products during the reporting quarter clocked $157 million against $148 million in Q1FY22 and $108 million in Q2FY21.
BUSINESS
Laurus Labs: New growth levers taking shape
The businesses to track for Laurus Labs, as far as future growth trajectory is concerned, are that of synthesis and biotech
BUSINESS
Cadila: Unfolding vaccine opportunity can offset US headwinds
For a longer term play, Cadila has a promising pipeline for NCEs (New chemical entities), biosimilars and injectables
BUSINESS
Dr Reddy’s: Aced by emerging markets' growth
While DRL is hit by pricing erosion in the US business, potential growth in the limited competition products underlines a positive outlook
BUSINESS
Lupin: Competitive pressure remains in the US market
Lupin guided for 16 percent EBITDA margin in H2 of FY22. While sequentially it indicates normalisation, given the elevated pricing pressure in the US market, execution will be closely monitored
BUSINESS
Hikal: 'China plus' opportunity adds to conviction for capex
For FY21 and FY22, Hikal is spending close to Rs 600 crore in capacity enhancement, where the major part of the benefit will accrue in FY24
BUSINESS
SRF: Inflation can impact capex payback period
For FY22, SRF's capex allocation stands at Rs 1,500-1,800 crore. The capex spent so far is nearly Rs 600 crore, which is expected to go up in H2
BUSINESS
Cipla: Focus shifts to FY23 launches
In the US market, while the Albuterol opportunity is stabilising for Cipla, traction for Arformoterol and the high-value product launch calendar in H2 FY23 is a key watch
BUSINESS
Ami Organics: What should investors do, post recent correction?
According to the management of Ami Organics, the priority for the acquired business of Gujarat Organics is to stabilise revenue and focus on reducing inefficiencies
MONEYCONTROL-RESEARCH
Gland Pharma: Operating leverage to offset input cost pain
As far as geographical diversification is concerned, Gland Pharma's foray into non-US markets is expected to accelerate. It's seen to leverage from products already approved in the US for launch in other markets
BUSINESS
Syngene: Look beyond the near-term input cost pressure
Syngene continues to guide for a mid-teen revenue growth in FY22. This appears possible, given the improved demand scenario and the strong traction in H1 FY22
BUSINESS
Navin Fluorine: Should investors accumulate the stock, post recent correction?
Recent initiatives present a significant opportunity as Navin continues to invest in talent and technology and get new inquiries from innovators
BUSINESS
What should investors do with this diagnostic play as COVID cases drop?
Krsnaa Diagnostics presents superior contract execution and scalability in radiology diagnostics
BUSINESS
Food colour companies are in capacity overdrive. What next for investors?
Indian food colour industry is set for dominance after the sharp scale-up in capacity expansion and end-market expertise. Vidhi specialty remains our preferred play
BUSINESS
China supply crisis: Can India’s chemicals step in?
In the last 20 months, COVID, logistics issues, and, now, power shortages have accelerated the global trend of de-risking the supply chain from China which would benefit the entire Indian chemical industry.
BUSINESS
How does the power crunch in China play out for Indian sectors?
China power outages is likely to keep prices of commodities at elevated levels; China-plus theme gets further push
BUSINESS
For Sumitomo Chemicals India, speciality is the trump card
The key near-term trigger for Sumitomo Chemical is the manufacturing of technical grade active ingredients for its parent company
BUSINESS
Fine Organics glued to green chemicals, may keep valuation premium
The medium-term growth in earnings for Fine Organics is expected to be driven mainly by volume growth in new capacities, better realisations and normalisation of input costs
BUSINESS
Fed signals early taper, but there is no immediate impact
The Fed continues to delink interest rate lift-off from tapering. Though the dot-plot of the September meeting hints towards one rate hike of 25 bps in 2022, Powell said “lift-off in policy rates” is not on its radar, as of now
BUSINESS
Ami Organics: Is it time to book profit as strong listing narrows valuation gap?
Post the strong listing, multiples are close to some of the larger players in chemicals, having their end-market as pharma.
BUSINESS
Vijaya Diagnostic: What does this regional player offer amid industry consolidation?
Going forward, technology will be the differentiator, and Vijay Diagnostic's differentiated hub- and-spoke model calls for attention
BUSINESS
SRF: Growth casts its net wide, but margins face pressure
The EBITDA margins of SRF are likely to moderate as the benefit from the operating leverage gets blunted by the margin contraction in the packaging business
BUSINESS
What's the trump card for this speciality chemical player?
Recent developments point to Clean Science and Technology's focus on enlarging product basket and a focus on green chemistry, which helps it differentiate from the rest
BUSINESS
Ami Organics IPO: A play on critical pharma intermediates
Intermediates are the key area where import dependence is huge, and, hence, a company like Ami Organics is likely to benefit
